Key facts
- Isospec Analytics’s last known valuation is $7.8M (Apr 2024).
- It has raised $2.0M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Venture Kick, Tiny Supercomputer Investment Company, Ecole Polytechnique Federale de Lausanne, Kickfund, Founderful — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Isospec Analytics
- ·The full record, as it builds
Funding rounds
No funding rounds for Isospec Analytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Isospec Analytics
Developer of molecular-identification technology designed to accelerate biomarker discovery and structural analysis in life-science research. The company platform offers AI-enhanced infrared fingerprinting, metabolite and glycan identification, biomarker discovery support, product-characterization services, and custom molecular-database generation, enabling biotechnology firms and pharmaceutical researchers seeking rapid, accurate molecular insights to streamline discovery workflows, improve target validation, and advance therapeutic and nutritional development with greater analytical confidence.
- Sector
- Healthcare
- HQ
- Denens, Switzerland
- Founded
- 2022
- Employees
- 9
- Website
- isospecanalytics.com/
- Ownership
- Privately Held (backing)
Isospec Analytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Isospec Analytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Isospec Analytics in its N-PORT filings yet. We sweep new filings monthly.